Having paid $300 million to enter the TIGIT space by acquiring ociperlimab in 2021, Novartis is now handing the candidate back to BeiGene.
[Fierce Biotech]
Home Newsletters Mammary Cell News Novartis Retreats from TIGIT, Handing $300M Candidate Back to BeiGene
